A Randomized, Double-blind, Placebo-controlled, Multisite, Phase 3 Study to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P) in Children and Adolescents With Epilepsy With Myoclonic-Atonic Seizures
Latest Information Update: 05 Feb 2025
At a glance
- Drugs Cannabidiol (Primary)
- Indications Epilepsy; Generalised epilepsy; Myoclonic epilepsies; Seizures
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Jazz Pharmaceuticals Inc
Most Recent Events
- 01 Nov 2023 Status changed from active, no longer recruiting to discontinued.
- 31 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 27 Oct 2022 Planned initiation date changed from 1 Sep 2022 to 1 Nov 2022.